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Background: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and
precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9–26 years.
There are limited data on the safety and immunogenicity of HPV vaccine in females with SLE, and none in
adolescents with SLE. Our study evaluates the safety and immunogenicity of recombinant quadrivalent HPV
vaccine, Gardasil, in adolescents and young women with SLE.
Methods: This is a prospective, open-label study. Exclusion criteria included disease exacerbation within past
30 days; rituximab or cyclophosphamide within 6 months; pregnancy. Vaccine was administered at months 0, 2,
and 6. Physical examination, SLEDAI scores and laboratory studies were performed at months 0, 2, 4, 6 and 7. Each
patient’s SLEDAI scores and laboratory profile in the year prior to vaccine administration were used as controls for
that patient. Primary outcome measures were change in SLEDAI and mean HPV antibody titers.
Results: 27 patients, 12 to 26 years, were enrolled; 20 completed the study. Nine had mild/moderate lupus flares.
Mean SLEDAI scores decreased from 6.14 pre-vaccination to 4.49 post-vaccination (p = 0.01). Of 12 patients with
lupus nephritis, two experienced worsening renal function during/after the study and progressed to renal failure
within 18 months of the study. Both had Class IV lupus nephritis with high chronicity scores (≥ 8) on renal biopsies
performed within one year prior to study entry. Seropositivity post-vaccine was >94% for HPV 6, 11, 16 and 18.
Conclusions: Quadrivalent HPV vaccine seems generally safe and well tolerated in this series of adolescents and
young women with SLE, with no increase in mean SLEDAI scores. Progression to renal failure in two patients was
most likely secondary to pre-existing severe renal chronicity and not secondary to HPV vaccination. Immunogenicity
to the quadrivalent HPV vaccine was excellent, with the seropositivity rate >94% in all four HPV types.
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Human papilloma virus (HPV) is the most common
sexually-transmitted infection in the United States, and
it is directly related to the development of cervical can-
cer [1]. It is estimated that 20 million Americans be-
tween 15 to 49 years of age, approximately 15% of the
population, have been or are currently infected with
HPV. About half of those who are infected with HPV
are sexually active adolescents and young adults 15 to
24 years of age [2]. Between 5% and 30% of individuals* Correspondence: arzu.soybilgic@gmail.com
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reproduction in any medium, provided the orinfected with HPV are infected with more than one HPV
type [3,4].
SLE patients were found to have an increased risk of
persistent HPV infection compared to healthy females.
They also have a higher risk for developing abnormal
cervical smears and squamous intraepithelial lesions
(SIL) of the cervix [5-7]. A recent study showed that
British women with a recent SLE diagnosis had signifi-
cantly higher levels of HPV infections, abnormal cervical
cytology, and SIL. HPV-16 and HPV-18 DNA positivity
were not associated with previous or current drug ther-
apy for the SLE patients in this study, suggesting
disease-specific factors might cause the high HPVal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rather than medication-related immunosuppression [8].
However, other studies have shown that women with
SLE also have a much higher risk of developing cervical
dysplasia if they are on immunosuppressive chemother-
apy, such as cyclophosphamide [9-11]. Therefore, it is
currently unclear whether these associations are host-
related, SLE syndrome specific, or, alternatively, repre-
sent a permissive effect of immunosuppressive therapy
on increased host susceptibility to high-cancer-risk
human HPV infections [12-14].
The quadrivalent human papillomavirus (HPV) vac-
cine, Gardasil®, is the first vaccine developed to protect
against infection with HPV types which are associated
with most genital warts and cervical cancer. The vaccine
series can be started at 9 years of age. Catch-up vaccin-
ation is recommended for 13 through 26 year old
females who have not yet received or completed the
vaccination series [1].
Because of their increased risk of persistent HPV in-
fections, vaccination against HPV in lupus patients is es-
pecially important. There may be a concern that patients
with SLE might not develop an adequate immune re-
sponse to the vaccine because of immune dysfunction
related to SLE itself and also the immunosuppression
secondary to treatment of SLE. However, many other
vaccines, including hepatitis B [15], pneumococcal
vaccine [16,17], and influenza vaccine [18], have been
shown to be immunogenic in the SLE population.
Although these vaccines have found to be generally safe
and well tolerated by SLE patients, lupus-like syndrome
and other autoimmune phenomena such as induction of
lupus anticoagulants, anti-Ro/La and anti-smith anti-
bodies have been reported following various immuniza-
tions [19].
There are limited data on the immunogenicity and
safety of HPV vaccination in young women with SLE
[20] and no studies that evaluate this vaccination in
adolescents with juvenile SLE. Our study primarily aims
to evaluate the immunogenicity of the quadrivalent HPV
vaccine in this patient population and assess its effects
on SLE disease activity.
Methods
Patient selection
Female SLE patients, 9 to 26 years of age, followed
at the pediatric and adult rheumatology clinics at the
University of Chicago were invited to participate in the
study. All patients fulfilled the revised ACR classification
criteria for SLE [21].
Exclusion criteria included: acute exacerbation of
disease within past 30 days which resulted in ≥ 3 points
increase in SLEDAI, an increase in corticosteroid dose,
initiation of a new immunosuppressive medication, orhospitalization; cyclophosphamide or rituximab treat-
ment in the last six months prior to screening; history of
allergic disease or reactions likely to be exacerbated by
any component of the vaccine; previous administration
of any HPV vaccines; pregnancy.
The Institutional Review Board of the University of
Chicago approved the study. Informed consent and
assent (if the patient was <18 years old) were obtained
from all participants. The study was conducted in
accordance with the ethical principles as described in
the Declaration of Helsinki and consistent with Good
Clinical Practice and applicable regulatory requirements,
including HIPAA.
Study protocol
This is an open label, prospective, pre-post intervention
study. Potential participants’ records were reviewed for
clinical manifestations of SLE, laboratory parameters,
SLE Disease Activity Index (SLEDAI) scores, and medi-
cations in the one year prior to study entry [22]. Each
patient’s SLEDAI scores and laboratory profile in the
year prior to vaccine administration were used as con-
trols for that patient. Prior to vaccination, a complete
history and physical examination were performed.
Patients were scheduled to receive three doses of 0.5 ml
of recombinant, quadrivalent HPV vaccine. (Gardasil®,
Merck & Co., Inc., USA), with the initial dose given at
study entry, and the second and third doses given two
and six months after the initial dose, respectively [23].
Patients were observed in the clinic for 30 minutes after
each vaccine dose for acute allergic reactions or syncope.
HPV vaccine-related side effects were evaluated system-
atically, including but not limited to pain, erythema,
swelling and itching at the injection site, fever, fatigue,
arthralgias, myalgias, headache, dizziness, syncope,
influenza-type symptoms, and signs and symptoms of an
acute allergic reaction including dyspnea and hives. At
study entry and at months 2, 4, 6 and 7, patients were
clinically evaluated, and physical examination and
laboratory data were recorded. Clinical manifestations of
SLE were carefully analyzed and a SLEDAI score was
calculated at each of the clinic visits.
Laboratory evaluation
Laboratory tests performed at months 0, 2, 4, 6 and 7 in-
cluded complete blood count (CBC), complete metabolic
panel (CMP), C3 and C4 complement levels, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), anti-
ds-DNA antibodies, urinalysis, and urine protein/creatin-
ine ratio. Anti-cardiolipin antibodies, β2-Glycoprotein
antibodies, lupus anti-coagulant, anti-RNP and anti-Smith
antibodies, and HPV antibodies were evaluated at months
0 and 7 of the study. All patients underwent urine preg-
nancy testing prior to administration of each quadrivalent
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nant were instructed to defer completion of their vaccin-
ation regimen until resolution of pregnancy and were
removed from the study.
Antinuclear antibodies were detected by indirect
Immunofluorescence using HEp-2 cells as substrate. Anti-
ds-DNA antibody was detected using IFA (neg <1:10 titer)
[24]. Anti-cardiolipin (neg <15 GPL, <12.5 MPL, <12.0
APL Units) and anti-β2-glycoprotein (β2GP) antibodies
(neg <20U/ml for IgG, IgM, IgA) were assessed by stan-
dardized enzyme-linked immunosorbent assay [25],
lupus anti-coagulant by DRVVT (neg <40.4 sec) and
PTTLA (neg <44.0 sec) and anti- RNP and anti-Smith
antibodies (neg <20 units) by single antigen EIAs (Inova
Diagnostics).
Type- specific immunoassays with type-specific stan-
dards were used to assess immunogenicity. These assays
measured antibodies against neutralizing epitopes for
each vaccine HPV type (HPV 6, 11, 16 and 18). The im-
munogenicity analyses were conducted in a per-protocol
immunogenicity (PPI) patient population. This popula-
tion consisted of individuals who were seronegative to
the relevant HPV types at enrollment, received all three
vaccinations, and did not deviate from the study proto-
col in ways that could interfere with the effects of the
vaccine. Immunogenicity was measured by the percent-
age of individuals who converted from seronegative to
seropositive for antibodies against the relevant vaccine
HPV type, and the cLIA (Competitive Luminex Im-
munoassay) Geometric Mean Titer (GMT, reported as
mili-Merck units (mMu)/ml) [26]. GMTs were measured
at month-7. HPV antibody titers were determined by test
kits, and cutoff values for seropositivity were titers at or
above 20, 16, 20 and 24 mMU/mL for HPV 6, 11, 16
and 18 respectively.Statistical analysis
Results are presented as mean plus-minus standard devi-
ation (SD) and percentages. Pre-post changes in SLEDAI
and other variables (ESR, CRP, C3, C4) were analyzed
using paired t-tests. Anti-ds-DNA antibody titers were
first log10 transformed (initial 0 titers were scored as 0
post transformation). Each patient’s pre-treatment and
post-treatment values were averaged, and the pre-post
changes analyzed using both a paired t-test and a non-
parametric, Wilcoxon signed rank test. Statistical signifi-
cance was set as P < 0.05 and 95% confidence intervals
were determined.Results
27 subjects, ages 12 to 26 years, were enrolled in the
study. 27, 25 and 20 subjects received one, two and three
doses of HPV vaccine, respectively.Demographics and clinical characteristics
22 of 27 patients had juvenile SLE, diagnosed before the
age of 16 years. The mean age at enrollment was
20.5 years and mean disease duration was 3.5 years. At
the time of study entry, seven patients were ≤ 18 years of
age. 14 subjects (51.8%) were African-American, 11
(40.7%) were Caucasian (non-Hispanic), and 2 (7.4%)
were Hispanic. Patients were taking the following medi-
cations to treat their SLE: hydroxychloroquine (100%);
prednisone (59.2%); mycophenolate mofetil (33.3%);
azathioprine (33.3%); methotrexate (22.2%). The mean
prednisone dose was 12.6 mg (range 0–36). In the past,
14.8% and 18.5% had received cyclophosphamide and
rituximab, respectively. Organ system involvement at
study entry: musculoskeletal 88.8%, hematologic 51.8%,
renal 44.4%, cutaneous 40.7%, neuropsychiatric 37%,
serositis 25.9%, cutaneous vasculitis 14.%, cardiovascular
7.4%, pulmonary 3.7%.
SLEDAI scores
In the 20 patients who completed the study, there was a
significant reduction in the mean SLEDAI scores from
6.14 pre-vaccination to 4.49 post-vaccination at month 7
(p- 0.010; 95% CI:-2.85 to −0.44) (Table 1). The two pa-
tients who withdrew from the study because of increasing
arthralgias had no increase in their SLEDAI scores of at
the time of study withdrawal or at their follow-up visits.
Laboratory data
Anti-ds-DNA antibody titers did not change significantly
post-vaccination (p = 0.17 by t-test; p = 0.25 by Wilcoxon
test). Levels of C3, C4, ESR and CRP remained stable.
(Table 1) The mean prednisone dose decreased signifi-
cantly over the course of the study (p = 0.005).
Induction of autoantibodies
None of patients who were negative for anti-RNP,
anti-Smith, anti-cardiolipin or anti-β2-glycoprotein anti-
bodies at study entry developed them during the study.
Lupus anticoagulant (LA) was present in 3 patients at
entry; in one of these patients, LA became negative by
end of study. Two patients who were LA negative at
study entry developed LA by month 7.
Withdrawals
7 patients did not complete the study. Two patients
moved out of the state, two chose to withdraw second-
ary to increased arthralgias after the second vaccine
dose, two were discontinued from the study secondary
to pregnancy, and one was lost to follow-up.
Pregnancies
A total of three subjects became pregnant during the
study. One became pregnant after the first vaccine, but
Table 1 Pre-vaccine and post-vaccine SLEDAI, laboratory values and prednisone doses of those who completed
the study
Variable n Pre-Mean (SD) Post- Mean (SD) 95% CI p-value
SLEDAI 20 6.14 (3.7) 4.49 (2.8) (−2.85, -0.44) 0.010
Anti-ds-DNA* 16 1.67 (0.28) 1.49 (0.25) (−0.46, 0.09) 0.17
ESR mm/hr 17 40.9 (21.4) 41.2 (25.6) (−6.7, 7.4) 0.91
CRP mg/L 15 4.48 (3.53) 3.30 (1.72) (−2.88, 0.52) 0.16
C3 mg/dl 20 92.3 (29.9) 93.0 (26.0) (−7.4, 8.7) 0.86
C4 mg/dl 20 18.2 (10.0) 20.1 (12.4) (−1.8, 5.7) 0.30
Prednisone (mg) dose 16 12.6 (10.8) 7.4 (5.9) (−8.5, -1.9) 0.005
*Log10 transformed.
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She then completed the three-dose vaccine schedule.
Two patients became pregnant after the second dose of
HPV vaccine, and these patients decided to continue
with their pregnancies and did not receive the third
dose. Both these pregnancies resulted in healthy new-
borns without any noted congenital defects.Adverse events
None of the patients had acute allergic, local or vaso-
vagal reactions after receiving HPV vaccine. Nine of 27
patients (33.3%) had a mild-moderate flare during the
study period, typically with symptoms similar to those
they experienced in flares before vaccine administration.
Five had arthralgias, 4 had rash, 2 had pleuritis, and 1
had peripheral neuropathy. One of the patients with rash
had a severe cutaneous flare after sun exposure, three
months after her second HPV vaccine. She was treated
with rituximab as this medication had successfully con-
trolled her lupus disease activity a few years earlier. Of
12 patients with history of lupus nephritis, two of four
with Class IV nephritis experienced worsening renal
function during/after the study and progressed to renal
failure within 18 months of the completion of the study.
Both patients had renal biopsies performed during the
year prior to study entry which showed marked glom-
erular sclerosis, interstitial loss and tubular necrosis.Table 2 Immunogenicity to HPV Vaccine





*Seropositivity and anti-HPV values were determined in the 16 patients who compl
available for HPV antibody measurement.
§ CI = Confidence Interval.
†cLIA GMT mMu = Competitive Luminex immunoassay, Geometric Mean Titers meaOne had a chronicity index (CI) of 8 out of 12, and the
other had a CI of 10 out of 12.Immunogenicity
Of the 20 patients who completed the study, 16 had
samples available at month 7 for analysis. Seropositivity
rates after three doses of the vaccine were 94.4%, 100%,
100%, and 94.4% for HPV 6, 11, 16 and 18, respectively
(Table 2). One patient had no antibody response to
HPV types 6 and 18 at month 7, and responses to 11
and 16 were positive but very low, with titers of 75 and
65 mMu/ml, respectively. This was the patient who re-
ceived rituximab between the second and third vaccine
doses.Discussion
In this small, non-randomized, non-controlled prospective
study, we have shown that the recombinant quadrivalent
HPV vaccine, Gardasil, was generally well-tolerated and
immunogenic in adolescents and young women with SLE.
In our patients, HPV vaccine did not result in an in-
crease in mean SLEDAI scores. Nine patients had mild/
moderate lupus flares during the study, typically with
symptoms similar to flares that they experienced during
the year before vaccine administration. Flare rates in our
study were similar to those in cited by Mok et al. who
studied HPV vaccination in young adults with SLE [20].95% CI § cLIA GMT mMu/ml † (95% CI)
(72.7, 99.9) 427.0 (203.4, 903.4)
(81.5, 100) 596.7 (303.6, 1173.2)
(81.5, 100) 2263.2 (1019.3, 5024.8)
(72.7, 99.9) 331.9 (159.8, 689.2)
eted the vaccine HPV series and had both pre- and post-vaccination serum
sured in milli-Merck units.
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ritis, two with Class IV nephritis experienced worsening
renal function during and after the study; both
progressed to renal failure. It is notable that both pa-
tients had high chronicity scores (≥ 8) on renal biopsies
performed within one year prior to study entry. Renal
failure would be an anticipated event based on the high
chronicity scores on the renal biopsy results on both
these patients, and therefore, does not appear to be
secondary to HPV vaccine administration [27-29]. The
10 other subjects with lupus nephritis had stable renal
function during the 7-month study and follow-up
period (8–20 months). None of these 10 patients had
chronicity scores >4 on biopsy.
Recombinant quadrivalent HPV vaccine was found to
be immunogenic in our patient population with sero-
positivity rates greater than 94% for all four HPV types.
This normal immune response to HPV vaccine occurred
despite corticosteroid treatment in approximately 60% of
our patients. Furthermore, the majority of our subjects
were being treated also with either azathioprine or
mycophenolate mofetil at time of immunization. The
conversion rate to seropositivity in our cohort of young
lupus patients was higher than in those SLE patients
who received the quadrivalent HPV vaccine in the study
by Mok et al. [20]. Seroconversion rate at month 7 in
Mok’s study was 74%, 76%, 92% and 75% to subtypes 6,
11, 16 and 18 respectively. Lower seroconversion rates
were noted in those patients on both mycophenolate
mofetil and prednisolone. They found no significant
correlation between HPV antibody response and age at
vaccination. However, other studies have shown that
post-vaccination GMTs were 2.0 to 2.9 fold higher in
younger girls (10–15 years of age) compared with sub-
jects 15–25 years of age [30]. It is conceivable that the
combination of older age of subjects in Mok’s study
(mean age was 5.3 years older than our population) and
immunosuppressive therapy led to a decreased HPV
antibody response.
Patients who received cyclophosphamide or rituximab
within 6 months of study entry were excluded from our
study, as these medications were found to cause an
impaired immune response to other vaccinations in SLE
patients [31,32]. Our experience, in which the one patient
who received rituximab during the vaccine protocol did
not develop immunogenicity to HPV, agrees with previous
experience of impaired immune response to vaccinations
in patients on rituximab and cyclophosphamide.
Given the increased risk of persistent HPV infection
and cervical dysplasia in women with SLE, demonstra-
tion of immunogenicity to HPV vaccine is especially im-
portant. A recent study from Denmark utilizing national
databases showed that nearly half of reported malignan-
cies in SLE patients may be HPV-associated [33]. Thestandardized incidence ratio (SIR) of anal and vaginal/
vulvar cancers in SLE patients compared to the general
population was 26.9 and 9.1 respectively. In a disease
such as SLE, which has increased morbidity from mul-
tiple causes, the prospect of being able to provide
prophylaxis against one possible cause of morbidity,
HPV-associated malignancy, is encouraging. SLE pa-
tients and other immunosuppressed populations will
need to be followed longitudinally to know whether the
HPV vaccine-induced immunogenicity will be efficacious
and provide protection over time against HPV infection
and its potential malignant sequelae.
There are reports of induction of autoantibodies in
patients with SLE after various immunizations [19,34].
In our study, HPV vaccine did not induce production of
autoantibodies such as anti-ds-DNA, RNP, Smith, or
anti-phospholipid antibodies. It is notable that a recent
post-marketing study of quadrivalent HPV vaccine did
not show an increased incidence of new autoimmune
diseases in healthy women receiving this vaccine [35].
Chao et al. observed almost 190,000 women for 6 months
following completion of the vaccine series and found no
increase in the incidence of new SLE cases, one of 16
autoimmune conditions monitored.
Limitations of our study were the relatively small sam-
ple size in which one-fourth of the subjects withdrew
from the study and the fact that this was a non-
controlled study. It is possible that the patients who
withdrew may have shown an increase in disease activity
or a lack of seropositivity to the vaccine series. Although
this study had no control group, we used each patient as
her own control, comparing disease activity during the
study period with disease activity during the year prior
to study enrollment.Conclusion
HPV vaccine was immunogenic, generally safe and
well-tolerated in our patient population of adolescents
and young women with SLE. Seropositivity to HPV
after three doses of the quadrivalent vaccine was
greater than 94% in all four HPV types. This excellent
response occurred even though the majority of our
patients were on prednisone and other immunosup-
pressive medication. Given that the increased risk of
persistent HPV infection and its complications in
women with SLE is well-established, and that quadriva-
lent HPV vaccine was immunogenic and well tolerated
in our small prospective study, administration of the
vaccine series to young females (9–26 years) with SLE
should be seriously considered. Continued vigilance
and clinical studies to assess for a possible negative
impact on disease activity in SLE patients receiving
HPV vaccine are warranted.
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